ESCLIM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESCLIM (ESCLIM).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), modulating gene transcription and non-genomic signaling pathways. It replaces endogenous estrogen in postmenopausal women.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to estrone and estriol; undergoes enterohepatic recirculation; conjugated with glucuronide and sulfate. |
| Excretion | Estradiol is primarily excreted in urine as glucuronide and sulfate conjugates (approx. 90%), with the remainder excreted in feces via bile (approx. 10%). |
| Half-life | The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, with significant interindividual variability. |
| Protein binding | Estradiol is approximately 97-99% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | The apparent volume of distribution for estradiol is about 1.2 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Transdermal bioavailability of estradiol is approximately 2-10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. |
| Onset of Action | Onset of clinical effect (e.g., symptom relief) occurs within 2-4 hours after transdermal application, with steady-state achieved after 2-3 applications. |
| Duration of Action | Duration of action is approximately 7 days per patch; clinical effects (e.g., vasomotor symptom reduction) persist for the duration of wear and decline after removal. |
| Molecular Weight | 272.38 |
Initial dose: 0.025 mg/day applied once weekly to clean, dry, non-irritated skin on lower abdomen or upper buttocks. Titrate based on symptoms. Maximum dose: 0.1 mg/day.
| Dosage form | SYSTEM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); caution advised. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance. |
| Pediatric use | Safety and efficacy not established; no standard pediatric dosing available. |
| Geriatric use | Initiate at 0.025 mg/day; titrate cautiously due to increased sensitivity and potential for adverse effects. Use lowest effective dose. |
| 1st trimester | Avoid use due to risk of fetal cardiovascular anomalies and neural tube defects associated with estrogen exposure during organogenesis. |
| 2nd trimester | Use only if clearly needed; has been associated with fetal feminization and potential long-term reproductive effects. |
| 3rd trimester | Avoid near term due to risk of uterine stimulation and premature delivery, as well as potential metabolic effects on the fetus. |
Clinical note
Comprehensive clinical and safety monograph for ESCLIM (ESCLIM).
| Placental transfer | Estradiol crosses the placenta readily; fetal serum concentrations approximate maternal levels. |
| Breastfeeding | Estradiol is excreted into breast milk in small amounts; may reduce milk production and alter breast milk composition. Monitor infant for gynecomastia or other hormonal effects. Generally, avoid use while breastfeeding; alternative agents are preferred. |
■ FDA Black Box Warning
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Also increases risk of stroke and deep vein thrombosis (DVT) in postmenopausal women. Do not use to prevent cardiovascular disease or dementia.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancer (except for selected cases)Estrogen-dependent neoplasiaActive thrombophlebitis or thromboembolic disordersHistory of thrombophlebitis or thromboembolic disorders associated with prior estrogen useHypersensitivity to any component of the product
| Precautions | Risk of endometrial cancer, cardiovascular disorders (stroke, DVT), breast cancer, gallbladder disease, hypertriglyceridemia, and fluid retention. Should be used at the lowest effective dose for shortest duration. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estrogen levels by inhibiting CYP3A4 metabolism; avoid concurrent consumption. No other significant food interactions. |
Loading safety data…
| Lactation Rating | L4 |
| Teratogenic Risk | Pregnancy Category X. Estradiol is contraindicated in pregnancy. First trimester exposure associated with urogenital tract abnormalities in female offspring (e.g., vaginal adenosis, clear cell adenocarcinoma) and cardiovascular anomalies. Second and third trimester exposure may increase risk of fetal genital anomalies (hypospadias in males). No therapeutic indication in pregnancy. |
| Fetal Monitoring | Not applicable in pregnancy (contraindicated). If inadvertent exposure occurs, monitor fetal growth and anatomy via ultrasound. Maternal monitoring includes blood pressure, liver function, and signs of thromboembolism. In breastfeeding, monitor infant for vaginal bleeding, breast enlargement, and jaundice. |
| Fertility Effects | Estradiol may inhibit ovulation at high doses via negative feedback on gonadotropins. Used therapeutically in some fertility protocols (e.g., endometrial preparation). Chronic high doses may impair fertility. Return to normal fertility upon discontinuation. |
| Clinical Pearls | ESCLIM (estradiol transdermal system) should be applied to clean, dry, non-irritated skin on the lower abdomen or buttocks, avoiding the waistline and breasts. Rotate application sites to prevent skin reactions. Do not apply to oily, damaged, or irritated skin. For optimal absorption, allow 5-10 minutes for the gel to dry before dressing. Avoid exposure to sunlight or tanning beds on the application site due to potential photosensitivity. In patients with intact uterus, concomitant progestogen is required to reduce the risk of endometrial hyperplasia. |
| Patient Advice | Apply the patch to clean, dry skin on lower abdomen or buttocks; avoid breasts and waistline. · Change patch twice weekly (every 3-4 days); do not apply to same site twice in a row. · Do not cut or damage the patch; discard used patches out of reach of children and pets. · Report any signs of blood clots (leg pain, chest pain, shortness of breath) or stroke (sudden severe headache, vision changes) immediately. · If you have a uterus, you must take a progestogen (e.g., progesterone) as prescribed to prevent endometrial cancer. · Avoid smoking while using this medication, as it increases risk of cardiovascular events. · If you miss a dose, apply a new patch as soon as remembered; do not wear more than one patch at a time. · Keep patches at room temperature; do not refrigerate or expose to extreme heat. |